Post-earnings recap
Reported
Tue, Aug 11, 2026
EPS actual
$-0.65
EPS est.
$-0.51
EPS surprise
-27.45%
1-day move
+2.18%
Immunome's second quarter results showed a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock reacted positively, rising by 2.18%, which may indicate that investors are looking past the EPS miss or are optimistic about future developments. Without further commentary from management, it is difficult to assess the underlying reasons for the stock's increase.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.65 | N/A | -27.45% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.
Immunome, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other diseases using its proprietary platform. Operating in the health care sector, its work is significant as it aims to harness the power of the immune system to create new treatments, which could address unmet medical needs.
Last quarter
In the last quarter, Immunome reported an EPS of -$0.48, which was better than the expected -$0.60, resulting in a positive surprise of nearly 20%. However, the stock still saw a slight decline of 1.35% the following day.
EPS beat streak
0Q
EPS beat rate
38%
Avg EPS surprise
-44.87%
Avg 1-day reaction
-0.97%
Overall expectations for Immunome's upcoming earnings are uncertain due to the lack of analyst estimates and management guidance. Investors are particularly focused on how the company will perform against its historical trends.
Bull case
The optimistic view hinges on a potential positive surprise in EPS and revenue, which could indicate strong demand for its therapies and lead to a significant stock price increase.
Bear case
On the downside, if the company reports a larger-than-expected loss or fails to provide clarity on its future growth, it could lead to a sharp decline in stock price.
The print will turn on these.
Q1
What will the EPS be for Q2-2026?
Given the company's recent history of EPS surprises, this number will be critical in determining market sentiment and stock movement.
Q2
What insights can management provide on revenue growth and future pipeline developments?
Clarity on revenue and future products will be essential for investors to gauge the company's growth potential and market position.
Why consensus could be wrong
The Street may underestimate the potential for Immunome to surprise positively on EPS due to its recent trend of beating expectations, despite the overall negative sentiment.
Supporting evidence
The company has shown a pattern of positive surprises in EPS, which could indicate an improving operational performance.
Options pricing suggests a significant move, indicating that traders are expecting volatility that may not align with consensus expectations.
Key risk
If the EPS comes in better than -$0.40, it could shift sentiment dramatically and challenge the current bearish outlook.
Pre-commit to what would confirm each case.
This quarter's performance is under scrutiny as investors look for signs of recovery and growth amid past losses.
Bull confirmed if
A reported EPS of -$0.40 or better would confirm the bull case, indicating improved operational efficiency.
Bear confirmed if
An EPS worse than -$0.60 would confirm the bear case, suggesting ongoing challenges in profitability.
What the market is pricing for the move.
Implied Move
±44.33%
Historical Avg
±3.4%
The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings report.
Options are pricing ±44.3% while IMNM has averaged ±3.4% over the last 8 prints — setup is pricing rich.
30d HV
54.2%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Immunome beats expectations, history suggests a potential stock increase of around 0.5%, confirming positive market sentiment.
In line / cautious
If results are in line with expectations, the stock may remain stable, but cautious commentary could lead to volatility.
Miss
A miss could lead to a decline of approximately 3.42%, reflecting investor disappointment and concerns about the company's future.
The lines on the call that would change the story.
—
Est. EPS
$0.20
Est. Rev
$609M
Impl. Move
±12.7%